{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:19:27Z","timestamp":1791839967877,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Atopic dermatitis (AD) is a common chronic inflammatory disease characterized by recurrent eczematous lesions and intense pruritus, and it can have marked negative impact on those affected. Pathophysiologically, AD is complex with genetic predisposition and environmental provocation being important contributors. Mechanistically these can promote epidermal barrier dysfunction, skin microbiome abnormalities and a skewed immune response which is predominantly type\u20102 immunity\u2010based. Our increased understanding of the immunological processes involved highlight a key role for interleukin\u201013 (IL\u201013). This mini\u2010review evaluates tralokinumab, a high\u2010affinity monoclonal antibody that specifically binds to and inhibits IL\u201013.<\/jats:p><jats:p>Based on dose\u2010finding study results, tralokinumab 300\u00a0mg every two weeks (Q2W) subcutaneously (SC) was investigated in three pivotal phase\u00a0III clinical trials in adults with moderate\u2010to\u2010severe AD not adequately controlled on topical corticosteroids alone. Tralokinumab was significantly superior to placebo regarding the proportion of patients achieving IGA 0\/1 and EASI\u201075 at week 16 (primary endpoints), as well as improving scores for worst daily pruritus, Dermatology Life Quality Index (DLQI), and Scoring Atopic Dermatitis (SCORAD) (secondary endpoints). The week 16 response was sustained during follow\u2010up, and treatment with tralokinumab was found to be well\u2010tolerated with an overall frequency and severity of adverse events comparable to placebo.<\/jats:p>","DOI":"10.1111\/ddg.14545","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T05:17:44Z","timestamp":1628918264000},"page":"1435-1442","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tralokinumab in atopic dermatitis"],"prefix":"10.1111","volume":"19","author":[{"given":"Andreas","family":"Wollenberg","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy Ludwig Maximilian University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig\u2010Holstein  Campus Kiel Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology Department of Dermatology Venereology and Allergy Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bieber","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital of Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.446"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16892"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14116"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1858802"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13160"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000499431"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2017.12.001"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-020-04720-1"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.4.supp.100"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","unstructured":"SimpsonE MerolaJF SilverbergJIet\u00a0al.Safety of specifically targeting interleukin\u201013 with tralokinumab in adult patients with moderate\u2010to\u2010severe atopic dermatitis: pooled analysis of five randomised double\u2010blind placebo\u2010controlled phase 3 and phase 2 trials. E\u2010poster at European Academy of Dermatology and Venereology (EADV) Virtual Congress; October 29\u201331 2020. P0218; Abstract 1464.","DOI":"10.25251\/skin.5.supp.11"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0253"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19699"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14545","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.14545","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T13:05:26Z","timestamp":1692536726000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.14545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/ddg.14545"],"URL":"https:\/\/doi.org\/10.1111\/ddg.14545","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"2020-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}